Editas Medicine, Inc. is making waves in the world of genome editing, dedicating itself to the development of transformative genomic medicines for serious diseases. Founded in 2013, the clinical stage company boasts a proprietary gene editing platform built on CRISPR technology. Currently, the company's focus is on developing EDIT-101, an innovative new drug in Phase 1/2 BRILLIANCE trials that targets Leber Congenital Amaurosis 10 and autosomal dominant retinitis pigmentosa, as well as EDIT-301, a clinical development gene-edited medicine which targets sickle cell disease and transfusion-dependent beta-thalassemia. But Editas Medicine, Inc.'s ambitions don't end there. The company is also exploring the development of transformative gene-edited Natural Killer cells for solid tumor cancers, as well as alpha-beta T cells and gamma delta T cell therapies to treat multiple cancers. Editas Medicine, Inc. has established research collaborations with industry leaders in the field, including Juno Therapeutics, Inc., with whom they are working to develop engineered T cells for cancer. They also have a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, exploring new gene editing medicines designed to treat a range of ocular disorders. Based in Cambridge, Massachusetts, the company was formerly known as Gengine, Inc. before changing its name to Editas Medicine, Inc. in November 2013.
Editas Medicine's ticker is EDIT
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Editas Medicine
It is editasmedicine.com
Editas Medicine is in the Healthcare sector
Editas Medicine is in the Biotechnology industry
The following five companies are Editas Medicine's industry peers: